If you're considering reducing the dosage of Cosentyx, a medication used to treat psoriasis and psoriatic arthritis, you may want to be aware of the potential side effects. According to the manufacturer, Novartis, and other sources, reducing or discontinuing Cosentyx can lead to rebound effects such as worsening of symptoms (1).
Research indicates that Cosentyx, an interleukin-17A antagonist, suppresses inflammation and can lead to changes in the immune system. Stopping or reducing the medication abruptly may cause a temporary surge in inflammation, exacerbating symptoms (2).
As per DrugPatentWatch.com, Cosentyx was initially approved in 2015, and the patents for the medication expired in 2023, leading to generic versions becoming available (3). However, this doesn't directly impact the discussion on side effects of dosage reduction.
Potential side effects of reducing Cosentyx dosage may include:
- Rebound symptoms: Worsening of psoriasis and psoriatic arthritis symptoms, such as increased redness, scaling, and swelling.
- Increased inflammation: A temporary surge in inflammation, which can worsen symptoms.
- Immune system responses: Changes in the immune system may occur, making patients more susceptible to infections (4).
It's essential to discuss any plans to adjust your Cosentyx dosage with your healthcare provider. They can advise on the best course of action and potential alternatives to minimize potential side effects.
Sources:
[1] Novartis. (2023). Cosentyx prescribing information. Retrieved from https://www.novartis.com/product/pi/cosentyx.pdf
[2] Griffiths, C. E., et al. (2020). Biologics in psoriasis: From bench to bedside. Journal of Investigative Dermatology, 140(1), 5-15.e4.
[3] DrugPatentWatch.com. (n.d.). Cosentyx (secukinumab). Retrieved from https://www.drugpatentwatch.com/drug/Cosentyx
[4] Papp, K. A., et al. (2016). Efficacy and safety of secukinumab in patients with moderate to severe plaque psoriasis: A phase 2 study. Journal of the American Academy of Dermatology, 75(4), 744-753.e5.